Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Glaxo Wellcome UK Limited trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Zinnat 125 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). |
Each tablet contains 125 mg cefuroxime (as cefuroxime axetil).
Excipient(s) with known effect:
Each tablet contains 0.00152 mg sodium benzoate (E211)
Each tablet contains Methyl parahydroxybenzoate (E218) and Propyl parahydroxybenzoate (E216)
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cefuroxime |
Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Aluminium foil blister pack with an aluminium lid.
Pack size: 6, 10, 12, 14, 16, 20, 24 and 50
Not all pack sizes may be marketed.
Glaxo Wellcome UK Limited trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
PL 10949/0095
15 October 1998
| Drug | Countries | |
|---|---|---|
| ZINNAT | Austria, Australia, Brazil, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
